non-cystic fibrosis bronchiectastis
CSL787_2001
STUDY OUTLINE
This international research study will test inhaled CSL787, an investigational drug. Inhaled CSL787 is a Human Normal Immunoglobulin Inhalation Solution. Inhaled CSL787 is expected to prevent infection related exacerbations.
In this research study, you will get either inhaled CSL787 or placebo.
To find out if this trial is suitable for you, please register below, or contact our Clinical Trials Team on 6151 0888 or email clinicaltrials@resphealth.uwa.edu.au
ELIGIBILITY & REQUIREMENTS
- Aged 18 – 85
- Confirmed diagnosis of Non-Cystic Fibrosis
WHAT'S INVOLVED
- The trial will run for approximately 56 weeks
- 7 clinic visits to the Institute for Respiratory Health in Midland
- A full health check by our doctors and nurses
- Reimbursement for travel expenses
- Personalised health care with our doctors and nurses
PRINCIPAL INVESTIGATOR
Dr David Manners (Midland)